The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients.
Lisa Salvatore
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Marta Schirripa
No relevant relationships to disclose
Gianluca Masi
No relevant relationships to disclose
Carlotta Antoniotti
No relevant relationships to disclose
Lorenzo Fornaro
No relevant relationships to disclose
Elisa Sensi
No relevant relationships to disclose
Cristiana Lupi
No relevant relationships to disclose
Francesca Bergamo
No relevant relationships to disclose
Sara Lonardi
No relevant relationships to disclose
Vittorina Zagonel
No relevant relationships to disclose
Gabriella Fontanini
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose